[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 86 pages | ID: E10B8F169871EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Drugs In Development, 2022, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 4, 4, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Eosinophilic Esophagitis - Drug Profiles
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Discontinued Products
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Jul 14, 2022: Dupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Jun 14, 2022: Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases
Jun 14, 2022: EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
Jun 01, 2022: Aqilion strengthens its operational team in clinical development prior to planned phase I study with drug candidate for inflammatory diseases
May 20, 2022: EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
May 20, 2022: FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder
May 16, 2022: Revolo Biotherapeutics announces presentations at upcoming medical meetings
Apr 04, 2022: FDA accepts Dupixent (dupilumab) for priority review in patients aged 12 years and older with eosinophilic esophagitis
Feb 26, 2022: Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
Dec 21, 2021: Allakos announces topline phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS study in patients with eosinophilic gastrointestinal diseases
Nov 17, 2021: Children's Hospital of Philadelphia receives $2 million gift to jump start new clinical trial for severe food allergies
Oct 28, 2021: Revolo Biotherapeutics activates clinical sites and opens enrollment in a phase 2 clinical trial of ‘1104 in eosinophilic esophagitis
Oct 26, 2021: Revolo Biotherapeutics to present at Stifel 2021 Virtual Healthcare Conference
Oct 25, 2021: EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Eosinophilic Esophagitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Eosinophilic Esophagitis - Pipeline by Adare Pharma Solutions, 2022
Eosinophilic Esophagitis - Pipeline by Akeso Inc, 2022
Eosinophilic Esophagitis - Pipeline by Allakos Inc, 2022
Eosinophilic Esophagitis - Pipeline by Amgen Inc, 2022
Eosinophilic Esophagitis - Pipeline by Aqilion AB, 2022
Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, 2022
Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, 2022
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, 2022
Eosinophilic Esophagitis - Pipeline by Ellodi Pharmaceuticals, 2022
Eosinophilic Esophagitis - Pipeline by EsoCap AG, 2022
Eosinophilic Esophagitis - Pipeline by GSK plc, 2022
Eosinophilic Esophagitis - Pipeline by Invea Therapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, 2022
Eosinophilic Esophagitis - Pipeline by Landos Biopharma Inc, 2022
Eosinophilic Esophagitis - Pipeline by Lanier Biotherapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by LEXEO Therapeutics LLC, 2022
Eosinophilic Esophagitis - Pipeline by Morphic Therapeutic Inc, 2022
Eosinophilic Esophagitis - Pipeline by Nexeos Bio, 2022
Eosinophilic Esophagitis - Pipeline by Pantherics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Pfizer Inc, 2022
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, 2022
Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, 2022
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Eosinophilic Esophagitis - Pipeline by Revolo Biotherapeutics Ltd, 2022
Eosinophilic Esophagitis - Pipeline by Serpin Pharma LLC, 2022
Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
Eosinophilic Esophagitis - Dormant Projects, 2022
Eosinophilic Esophagitis - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Eosinophilic Esophagitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications